FloBio is pioneering a novel point-of-care (POC) diagnostic platform to address the decision making challenges and preventable consequences of inadequate assessment of bleeding/thrombotic risk. Providing rapid and accurate detection of blood function will enable clinicians to make evidence based and cost effective decisions for patients in emergency, critical care settings where time and actionable information is critical. The real-time analysis of flowing blood and direct measurement of blood function metrics presents a significant advantage over traditional coagulation tests, leading to rapid, sensitive detection of clotting status. A portfolio of POC tests is planned opening a multi-billion dollar market opportunity. FloBio’s initial market entry addresses a growing number of individuals (>21M globally) who are taking a new class of blood thinner medications, Direct Oral Anticoagulants (DOACs), and at increased risk of bleeding and complications in emergency critical care setting.
Login or Register
You need to be logged in to use this feature.
Further Activities to have a look at